Though there are few direct hints at how the company plans to translate its findings to a clinical test, its early data has captured the attention of the cancer community.
The financing round will support Grail's ongoing development and validation of early cancer detection products.
The NGS-based test improves on a previous PCR-based version and detects circulating DNA from Epstein Barr virus that is shed from cancer cells.
The recent agreement between Freenome and Biognosys suggests a role for proteomics as developers of genomic-based cancer detection tests look beyond ctDNA.
In a training subset of the larger cohort, the company was able to develop classifiers that detected many cancers while minimizing false positives.
The firm plans to launch a nasopharyngeal carcinoma test in Asia this year and is developing breast cancer tests to supplement mammograms.
Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.
There were fewer mergers and acquisitions in the omics space in 2017, breaking a two-year streak of growth — however, the deals themselves stayed fairly large.
Using Epstein-Barr virus DNA as a marker, investigators uncovered several individuals with early-stage nasopharyngeal cancers in a large screening effort in China.
CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.